Planning a BBQ? Check out these 5 food safety tips first
Trish Twohig, Director of Food Safety with Safefood, shares five important BBQ safety tips.
Whether you're a seasoned host or just someone who loves to fire up the barbecue, there are some essential rules you should never ignore when handling food safely in summer.
As someone who works year-round to promote safe food practices, I'm proud that we at Safefood are supporting Safe2Eat — a major EU-wide campaign led by the European Food Safety Authority that empowers consumers with science-backed food safety information.
Through this and beyond, we're here to help ensure your guests are in safe hands every time you serve. These are the most common mistakes I see every year at summer BBQs, and what you can do to avoid them.
1. Clean equipment
If you're digging out the barbecue for the first time in a long time, be sure to give it a clean. Grease and old food residue can linger on your grill from last summer. Give the metal rack a good scrub with oven cleaner or a damp brush dipped in baking soda. Rinse it thoroughly with hot, soapy water.
A clean grill helps reduce contamination risks and ensures your food tastes great and cooks evenly. And give it a clean before you tidy it away. It's easier to clean when it's warm or cooling down than when the residue is baked onto it!
2. Timings and leftovers
One of the many food safety challenges in summer is keeping perishable food at safe temperatures. When entertaining guests, we might want to serve little bites or snacks while they wait for the burger or hot dog to be served. But when showing up to a barbecue, I never want to see salads or dips sitting in the sun.
When food is sitting outside in the sun, the direct sunlight and warmer temperatures are ideal for harmful germs to grow quickly.
My tips would be to:
Keep perishable foods like salads, coleslaw and dips in the fridge until just before serving.
Use cool boxes with ice packs to transport and store chilled foods if you're not serving them immediately.
Keep raw meat chilled until you are ready to grill. Don't leave it sitting out while you are lighting your barbecue.
And who doesn't love leftovers? Once everyone's had their fill, pack up any leftovers quickly. Leaving them on the garden table isn't just an invitation for bacteria to multiply, but insects, too.
Cover any leftovers and let them cool in the kitchen. Do this within two hours of cooking. Eat them within three days then it's time to throw them out. If you want to reheat them, do so until it is piping hot and only reheat them once.
If I have any doubts about a leftover and its safety, I play it safe and throw it out! No leftover is worth the risk of food poisoning.
3. Prep your food
When planning a BBQ, I always prep the food I am cooking beforehand. That includes any frozen food. Cooking frozen meat straight from the freezer is a guaranteed way to end up with a raw centre and burned edges.
Always fully defrost meat before grilling. It should be done on a plate covered overnight, on the bottom shelf of the fridge. This helps prevent any drips that could contaminate other foods.
And when you are cooking meat on the barbecue, make sure the grill is ready. When using a charcoal BBQ, light it well in advance. You may want to throw on your burgers or sausages as soon as you see the flames, but don't. Wait until the flames have died down before you start grilling. It allows for even and safer cooking.
4. Avoid cross-contamination
Cross-contamination is one of the most common causes of food poisoning at BBQs. Raw meat juices contain harmful bacteria that can easily spread if you're not careful. There are simple but effective ways to stop the spread of bacteria.
When having a barbecue, make sure to always:
Use separate utensils, plates, and cutting boards for raw and cooked meat.
Wash your hands thoroughly before and after handling food.
Never place cooked meat back on a plate that holds raw meat.
Keep ready-to-eat items like salads, dips, and sauces well away from raw meat.
I would recommend doing a check of your fridge before you do your shop for your barbecue. When storing food in the fridge for a barbecue, it can be difficult to organise foods separately and safely. So, check your fridge and make some space!
5. Finding the right temperature
I can't emphasise this enough: just because it looks cooked doesn't mean it is.
This is important especially with poultry, pork, minced and skewered meat, such as burgers, sausages and kebabs. While the outside may look cooked (and in some cases burnt), the inside can still be raw.
The best tool I can ask you to use is a meat thermometer. Insert it into the thickest part of the meat and check that it reaches 75°C.
No meat thermometer? No problem. You can check to see if the meat is cooked by cutting into it and seeing that:
They are piping hot all the way through
There is no pink meat left
The juices run clear
On the day of the barbecue, I will most likely be busy running around. That's why I like to pre-cook the meat in the oven, then I can pop it on the grill for that classic BBQ flavour. It's a time saver and gives me confidence in knowing the meat is fully cooked.
Hosting a BBQ should be enjoyable, not stressful. A little planning and common sense go a long way when it comes to food safety. By taking the time to prep to avoid these common mistakes, you will be a grill master in no time.
Most importantly, you'll be protecting your guests from any unwanted surprises, and they will remember your BBQ for all the right reasons.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
2 days ago
- Irish Examiner
Synthetic drugs pose 'emerging threat' across Ireland and Europe
Europe is facing an emerging threat from synthetic drugs — including artificial substances that mimic cannabis, heroin and stimulants — the EU drug agency has warned. It has documented 'unprecedented imports and seizures' of synthetic cathinones, which are chemically similar to cathinone, a stimulant. The European Union Drug Agency also flags the 'rising availability' of fake medicines containing highly potent nitazenes — a synthetic opioid that led to overdose outbreaks in Dublin and Cork at the end of 2023 and in several Irish prisons in 2024. In its European Union Drug Report 2025, the agency highlights a doubling in the strength of cannabis resin over the last decade and the risks posed by high-potency cannabis extracts and edibles, like jellies. The report said semi-synthetic cannabinoids have 'spread rapidly' in recent years. One of these substances, HHC, has been linked to serious psychological effects, including among schoolchildren in Cork in November 2023. HHC can be purchased legally in jellies and vapes from stores in Ireland, despite repeated concerns of medical experts. New provisions are being drafted to fill the legislative gap. The report is also alerting users of the dance drug ecstasy that they are exposing themselves to 'unpredictable health risks', as the content of the active ingredient, MDMA, has 'increased markedly'. It said the average MDMA content in ecstasy tablets has increased from about 84mg in 2011 to between 138mg and 158mg now, with some tablets containing up to 350mg. This warning chimes with an alert issued last week by the HSE, which said that one in four ecstasy pills it had tested in 2024 had more than 200mg of MDMA, which, it said, was more than double the typical adult dose. Issuing the alert as part of its harm reduction strategy for the coming festival season, the HSE said high-strength MDMA pills, powders and crystals in circulation increased the risk of 'getting very sick', including accidental overdose. The European Union Drug Agency report mentioned the HSE harm reduction campaign at music festivals, which included the testing of samples handed over to surrender bins, enabling live dissemination of rapid risk alerts to potential users. The agency said that similar to the more extensive trend with cannabis, MDMA had been found in edibles — such as sweets and lollipops — in some countries. 'As with cannabis edibles, these products pose difficulties in regulating dosage and increase the risk of inadvertent consumption, especially a concern if they are consumed by minors,' the report said. It said seizures of synthetic cathinones had increased from 2.1 tonnes in 2021, to 27 tonnes in 2022 and to 37 tonnes in 2023. The report said while synthetic cathinones have been shown to have similar effects and potential harms as stimulants like MDMA and amphetamine, they are a broad range of substances, some of which may have 'more severe' effects. The drug agency said synthetic cannabinoids were widely available online and in shops and include flavoured jellies and vapes. 'Their accessibility and supposed legal status may attract both cannabis users and first-time users, potentially including youth and children,' it said. Read More Quantity of cocaine seized in EU countries has almost doubled in past three years
Irish Examiner
2 days ago
- Irish Examiner
Quantity of cocaine seized in EU countries has almost doubled in past three years
The quantity of cocaine seized in EU countries has almost doubled in the past three years, according to the bloc's drugs agency. The European Union Drug Agency said 419 tonnes of cocaine was seized in 2023, compared to 323 tonnes in 2022 — up 30%. Figures previously produced by the agency showed there were 303 tonnes seized in 2021 and 211 tonnes in 2020. The agency said cocaine was the second most common problem drug for people seeking treatment for the first time, accounting for 26% of all new entrants. Irish figures show cocaine was the most common problem drug for new entrants in 2023, accounting for 46% of all new entrants. The agency said that, given there was a long gap between first use and seeking treatment, there could be a 'surge' in treatment demand for cocaine in the coming years. In its European Union Drug Report 2025, the agency also reports: Increased availability of synthetic (artificial) cathinones, with 'unprecedented imports and seizures', resulting in some users not knowing what they are buying; A rise in the potency of cannabis resin, with a doubling in the amount of the active THC ingredient over the last decade, and a wide range of other high-potency cannabis products, such as edibles and extracts; Wider availability of semi-synthetic cannabinoids, a combination of chemicals designed to mimic the effects of cannabis and cannabis itself, including HHC, seen in Ireland; Rising availability of fake medicines containing nitazenes, the highly potent synthetic opioid that caused emergencies in Dublin and Cork among the homeless heroin-using communities in late 2023 and in a number of Irish prisons in 2024; Greater diversity in drug polices in Europe, with Germany, Luxembourg, Malta and Netherlands, allowing for home growing of cannabis, non-profit growing clubs and cannabis use in private — but the European Union Drug Agency urges the policies be evaluated to grasp their impact on health and security. The agency said the availability of high-potency cannabis extracts and edibles was of 'particular concern', as they had been linked to acute drug-toxicity presentations in hospital emergency departments. The report said that, in addition, some cannabis products may be adulterated with potent synthetic and semi-synthetic cannabinoids. 'In Ireland, nitazenes were mis-sold as heroin in 2013 and as benzodiazepines in 2024, resulting in inadvertent consumption and multiple overdoses,' report said. Picture: Leah Farrell/ It said many of the semi-synthetic products involved HHC, with hospital cases typically involving 'young people' after consuming jelly sweets or other edibles. The agency said despite the crackdown on opium production by the Taliban regime in Afghanistan, the production and trade in heroin has continued, which it said was due to 'significant opium stocks'. It said the sizeable profits for organised crime groups from the cannabis trade has resulted in violence between competing gangs. In relation to synthetic opioids, such as nitazene, it said: 'In Ireland, nitazenes were mis-sold as heroin in 2013 and as benzodiazepines in 2024, resulting in inadvertent consumption and multiple overdoses.' The report said countries with large container ports, that were being used by cocaine traffickers, were experiencing 'high levels of drug related crime', including corruption of port staff, intimidation and violence. The MV Matthew, where 2.25 tonnes of cocaine was seized in September 2023. Picture: Larry Cummins It said Columbia, Brazil and Ecuador were estimated to have contributed to the increase in cocaine trafficked into Europe. It said in addition to commercial containers, trafficking gangs used other methods in a bid to evade detection. 'For example, in September 2023, Ireland seized 2.25 tonnes of cocaine from a cargo ship off its southern course,' the report said, referring to the MV Matthew, prosecutions in relation to which are before the criminal courts. Launching the report, Magnus Brunner, European Commissioner for internal affairs and migration, said: 'The illicit drug trade poses a severe threat to the health and security of our citizens. It fosters an environment of intimidation and corruption, undermining the fabric of our communities, businesses and institutions. The fierce rivalry among criminal networks not only heightens gang violence and homicides but also increasingly involves the recruitment of minors into criminal activities.' European Union Drug Agency executive director Alexis Goosdeel said: 'Amid global instability and fast-changing drug trends, Europe faces multiple challenges that put its citizens at risk. The rise of highly potent substances and more complex patterns of drug use is placing health and security systems under strain.'
RTÉ News
2 days ago
- RTÉ News
Bitter pill: EU exploits Trump anti-science climate to forge deal on medicines
The EU's sweeping new rules on the regulation of medicines has been one of the most bitterly contested pieces of legislation in recent times, with fierce lobbying by the pharma sector - particularly in Ireland - and member states divided on which to prioritise: cheaper medicines for patients, or a regulatory environment that supports indigenous European manufacturers in the face of US dominance. After two years of deadlock, 26 member states have agreed on a compromise proposal, with only Malta - which has its own small-market medicines challenge - abstaining. Ironically, it was the Trump administration's hostility to science and medicine regulators that convinced EU member states that the moment to finally agree on a new set of rules was at hand. "In the US you have a chaotic situation," says one source familiar with negotiations, "between [Health Secretary] Robert Kennedy Jr, who doesn't believe in science or vaccines, and the Trump administration, which has sacked three and a half thousand people from the Food and Drugs Administration. "There was a sense in Europe that we should try to get this proposal settled so that we have a stable system in Europe when there's instability elsewhere." The legislation will now go to the European Parliament, where negotiations between MEPs, the member states and the European Commission, begin on 17 June. There are hopes that the entire package could be adopted by the end of the year. The European Commission first proposed overhauling the EU's medicines regime in April 2023, as Europe was emerging from the Covid pandemic. The EU was reeling from the strain the emergency put on health systems and on the availability of certain kinds of medicines, with a deepening awareness that Europe was overly dependent on China and India for drugs such as antibiotics. At the same time, digitalisation and the availability of clinical data were opening up new possibilities in how medicines are developed and used. Despite that, innovative therapies were not reaching patients across Europe at the same speed while in some member states patients did not have access to medicines they needed due to shortages. The instinct to reduce health spending further has been given fresh impetus by the expected surge in EU defence expenditure following Russia's invasion of Ukraine. Overall, the pharma package sought to boost the competitiveness of the sector, reduce the administrative burden - and the over-reliance on India and China - and to tackle the environmental impact of drug manufacture and use. The central, most divisive issue was around the protection that big European pharma countries would have in holding on to clinical data before generic manufacturers - who could produce cheaper drugs - could access it. It became a straightforward contest between the competing interests of big pharma, which argued that companies needed the protection in order to invest more in life-saving domestic European research and innovation, and those countries which were more interested in lowering the cost of medicines and making those medicines more accessible to patients. The legislation was always going to face a stormy passage. "The difficulty was that the countries that didn't have pharmaceutical industries were very much opposing the regulatory data protection (RDP) element because all they were interested in was making medicines available to citizens," says Fianna Fáil MEP Billy Kelleher, a substitute member of the European Parliament health committee. "Eastern European countries like Poland, Romania, Bulgaria and others would have been very, very reluctant to support the strong protection of regulatory data, while it was the old West, countries like Ireland, Belgium, Italy, Germany and the Netherlands that have big manufacturing and pharma centres, a lot of research and development, who were pushing for it." The new rules would attempt to reconcile the issue of regulatory data protection, which theoretically encourages pharmaceutical companies to invest more in life-saving medicines, with the need to make drugs more affordable. Under existing EU rules, pharma companies were entitled to keep clinical data for eight years - the so-called regulatory data protection (RDP) before they were obliged to make it accessible. After the eight years was up, generic producers could file an application to use the data, at which point the patent holder enjoyed a further two - and sometimes three - extra years of protection. Under the commission's 2023 proposal, there would be a two-year reduction in the baseline RDP to six years, with an extra two years of protection. However, pharma companies could claw back a further two years of protection - extending RDP to ten years. The ten-year protection period would be available if the patent holder won approval for significant new innovations (one extra year of protection), if the product addressed an "unmet medical need", ie, where there was product authorised in the EU for a particular disease, or where the disease was associated with a high death-rate (such a situation would merit an extra six months of market protection), or if the manufacturer conducted clinical trials or extended access to all member states (another six months). Essentially, the commission was attempting to balance the need to reward medicines that meet the greatest clinical need, while speeding up access to generic producers who will make drugs that are cheaper. However, the new rules were facing hostility from traditional pharma manufacturing countries such as Germany, France, Denmark and the Netherlands, who argued that a shorter clinical data protection period would stymie research. The Irish Times reported on a full scale lobbying effort by industry, including a claim in a letter to Tánaiste Simon Harris by the Irish Pharmaceutical Healthcare Association (IPHA) that the proposal could lead to a 22% drop in new medicines being developed over the coming decade. It is understood there were tensions between the IDA and Enterprise Ireland, who shared the concerns of industry, and the Department of Health, which was more concerned with lowering the cost of medicines and making them more accessible. A number of sources have said that while member states with important pharma sectors went public two years ago, when the commission first proposed reducing clinical data protection from eight years to six, in demanding the status quo of eight years, Ireland remained on the fence, and did so right up until a key meeting of EU ambassadors on 21 May. On that date, Ireland joined a blocking majority of ten countries - including Belgium, Denmark, the Netherlands and Germany - to oppose the latest Polish proposal that would have essentially increased the RDP by one year to seven, but short of eight. As a result of that blocking minority, the Poles came back with another compromise text, which is - to all intents and purposes - a return to eight years, with various caveats and conditions designed to make medicines cheaper and more accessible (one part of the text aims to ensure that medicinal products are available in all member states and provides for regulatory action if the marketing authorisation holder does not comply). Officials say the text provides more reassurance for generic producers, and will cut timelines for authorised medicines to get to market. There are other measures, including making it easier to have multi-country and multilingual medicine packs, which should reduce production costs and make it easier to move medicines around Europe. At yesterday morning's meeting of EU ambassadors, the new text received overwhelming support. The IPHA are understood to be broadly satisfied with the compromise. In a statement, the organisation said it "believes the [member states] position represents a more balanced approach than had originally been proposed by the Commission. "As the legislative process enters the final phase, EU decision makers must continue to find solutions that will keep Europe competitive through a predictable and globally competitive environment for research, development and manufacturing, while ensuring fairer access to innovative medicines for patients across the EU." Support is not uniform. The chief executive of the Confederation of Danish Industry Lars Sandahl Sørensen accused member states of triggering a potential flight of European industry to Trump's America. "We are de facto making the EU's pharmaceutical industry less competitive and thus European society vulnerable," he said. The European pharma lobby group EFPIA described yesterday's position by member states as "a missed opportunity to position Europe's life sciences sector at the forefront of global competition". In a statement, EFPIA said: "The choice to reduce intellectual property protections for pharmaceutical companies makes Europe less attractive, discouraging investment and jeopardising the development of innovative treatments in Europe without addressing the underlying barriers and delays to patient access." There is some scepticism over the industry's seeming exploitation of Donald Trump's persistence in threatening tariffs on European pharmaceutical exports and reshoring manufacturing to the US. In April the industry wrote to commission president Ursula von der Leyen, suggesting that €50.6 billion in capital investment and €52.6bn in research and development expenditure were at risk if the EU continued to over-regulate the pharma sector. "Unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US," EFPIA warned. Officials suggest the upcoming Critical Medicines Act (CMA) will further boost access to cheaper medicines. Drugs such as those for diabetes or HRT have been susceptible to disruption and shortages in recent years because they are often generic and produced outside the EU. The CMA will aim to encourage more manufacturing of such drugs in Europe. The action now moves to the European Parliament, where so-called trilogues - three way negotiations between member states, the Commission and MEPs - will further shape the legislation. Last year the parliament adopted its own position, calling for an RDP of seven and a half years with the possibility of some extensions. The parliament has since moved to the right, following last year's elections, so it remains to be seen if further battles are expected.
